艾迪注射液膀胱灌注预防非肌层浸润性膀胱尿路上皮癌术后复发的效果

Effect of Aidi Injection by Intravesical Instillation on the Prevention of Postoperative Recurrence in Non-Muscle Invasive Bladder Urothelial Carcinoma

目的:探讨艾迪注射液膀胱灌注预防非肌层浸润性膀胱尿路上皮癌术后复发的临床效果及不良反应。方法:选择2008年1月—2011年6月非肌层浸润性膀胱尿路上皮癌术后患者67例,将其分为观察组(n=34)与对照组(n=33)。对照组采用丝裂霉素进行膀胱灌注,观察组采用艾迪注射液进行膀胱灌注,观察比较两组患者的治疗效果及不良反应。结果:术后随访1～4年,观察组肿瘤复发率为16.75%,对照组肿瘤复发率为48.56%,两组患者术后肿瘤复发率差异有统计学意义(P<0.05)。观察组未出现明显不良反应,对照组6例(18.18%)出现不良反应,两组不良反应发生率比较差异有统计学意义(P<0.05)。结论:非肌层浸润性膀胱尿路上皮癌患者应用艾迪注射液膀胱灌注预防术后复发临床效果较好,不良反应少,安全可靠,值得临床进一步推广。

Objective：To Investigate the effect of Aidi injection by Intravesical instillation on the prevention of postoperative recurrence in non-muscle invasive bladder urothelial carcinoma.Methods： A tatal of 67 non-muscle invasive bladder urothelial carcinoma patients were divided into observation group（n=34） and comparison group（n=33） from January 2008 to June 2011.The patients in comparison group were treated with intravesical instillation of mitomycin C,and the patients in observation group were treated with intravesical instillation of Aidi injection.Therapeutic effects and adverse reactions have been observed.Results： Patients have been followed up for 1-4 years.Compared with the comparison group,the tumor recurrence rate was significantly lower in observation group（16.75% vs 48.56%,P0.05）.Adverse reactions have not been found in the observation group.There were 6 cases（18.18%） of adverse reactions in the comparison group.The difference in the incidence of adverse reactions was statistically significant between the two groups.Conclusions： It is effective,safe and reliable to apply Aidi injection by intravesical instillation for the prevention of postoperative recurrence in non-muscle invasive bladder urothelial carcinoma.